Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).
Franco Cavalli
No relevant relationships to disclose
Brendan Rooney
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Lixia Pei
Employment or Leadership Position - Janssen Research & Development
Helgi Van De Velde
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Tadeusz Robak
Consultant or Advisory Role - Johnson & Johnson (U); Roche (U)
Research Funding - Johnson & Johnson; Roche